Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus

Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis

(2018) Dag Leonard et al.   ANNALS OF THE RHEUMATIC DISEASES

Epratuzumab for the treatment of systemic lupus erythematosus

(2018) Daniel Geh et al.   Expert Review of Clinical Immunology

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

(2018) Zhi-Wei Lai et al.   LANCET

Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus

(2018) Hiroshi Kato et al.   Arthritis & Rheumatology

Rapamycin for refractory discoid lupus erythematosus

(2018) Mitchell Herold et al.   Dermatologic Therapy

Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients

(2018) Rabea Asleh et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis

(2018) Desmond Y.H. Yap et al.   JOURNAL OF RHEUMATOLOGY

Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years

(2016) Zachary Oaks et al.   Current Rheumatology Reports

Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial

(2015) K. L. Bride et al.   BLOOD

Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus

(2015) Mathilda Björk et al.   BMC MUSCULOSKELETAL DISORDERS

Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases

(2015) Andras Perl   Nature Reviews Rheumatology

Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register

(2015) Anna Ighe et al.   ARTHRITIS RESEARCH & THERAPY

Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis

(2015) Elizabeth L. Yanik et al.   Cancer Medicine

ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA/AMPK signaling in advanced atherosclerosis

(2014) Yuyan Xiong et al.   Autophagy

Dysregulation of anergy-related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in restoring regulatory T cells

(2014) Leontina M. Banica et al.   International Journal of Rheumatic Diseases

Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome

(2014) Guillaume Canaud et al.   NEW ENGLAND JOURNAL OF MEDICINE

hsBAFF promotes proliferation and survival in cultured B lymphocytes via calcium signaling activation of mTOR pathway

(2013) Zhen Ke et al.   CYTOKINE

Cancer risk in systemic lupus: An updated international multi-centre cohort study

(2013) Sasha Bernatsky et al.   JOURNAL OF AUTOIMMUNITY

Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus

(2013) Z.-W. Lai et al.   JOURNAL OF IMMUNOLOGY

Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register

(2013) Martina Frodlund et al.   BMJ Open

Mechanisms of Premature Atherosclerosis in Rheumatoid Arthritis and Lupus

(2012) J. Michelle Kahlenberg et al.   Annual Review of Medicine

Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience

(2012) DESMOND YH YAP et al.   NEPHROLOGY

Unmet medical needs in systemic lupus erythematosus

(2012) Aisha Lateef et al.   ARTHRITIS RESEARCH & THERAPY

Preferences, quality of life and public health

(2009) R. Leidl   EUROPEAN JOURNAL OF PUBLIC HEALTH

Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice

(2008) SL Lui et al.   LUPUS

Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway

(2008) Weiping Cao et al.   NATURE IMMUNOLOGY